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Epidermal, Sebaceous, and
Melanocytic Nevoid Proliferations Are
Spectrums of Mosaic RASopathies
Su Luo1 and Hensin Tsao1,2
Growing evidence demonstrates that various nevoid proliferations such as
keratinocytic epidermal nevi and nevus sebaceous result from somatic mosaicism.
Many of the mutations identified have been within the RAF/RAS/MAPK pathway,
hence supporting the previously introduced term "mosaic RASopathy" for these
nevi. In this issue, Kinsler et al. were among the first to characterize certain
pigmented melanocytic nevi that may also fit this paradigm. To better frame these
findings, we provide a summary of the analogous genotypic profiles for epidermal
and melanocytic nevi from recent studies.
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Mosaicism is the presence of two dis-
tinct populations of cells that express
differing phenotypes in one organism,
resulting from a postzygotic mutation.
Cutaneous mosaicism, being readily
apparent, represents a unique opportu-
nity to study such genetic events. Var-
ious patterns found on the skin, such as
the lines of Blaschko and the checker-
board and phylloid (leaf-life) patterns,
are well-known manifestations of
mosaicism (Happle, 1993).
Nevoid proliferations make obvious
mosaic presentations when they are
extensive. Examples include systema-
tized keratinocytic epidermal nevi
as well as the Schimmelpenning
syndrome, in which a widespread
nevus sebaceous (NS) is associated with
extracutaneous defects. The molecular
basis for these phenotypic expre-
ssions are continually being elucidated
(Bourdeaut et al., 2010; Groesser et al.,
2012). In addition, inferences from
these observations have led to con-
comitant genetic analyses of the
common keratinocytic epidermal nevus
(KEN) and NS. These analyses revealed
the equivalent role of mosaicism in
these isolated nevi, which also often
follow the lines of Blaschko. Strikingly,
several common hotspot mutations in
the RAS oncogenes are recurrent in such
nevi.
Table 1 provides a summary of studies
genotyping the available mosaic pheno-
types divided into nevoid types. Hafner
et al. (2011) first presented a case of a
systematized KEN with multiple urothe-
lial carcinomas stemming from a mosaic
HRAS p.G12S mutation. They subse-
quently showed that an adjacent HRAS
mutation, p.G13R, was present as the
somatic mutation in nearly a third of
KEN, identifying it as a new hotspot for
mutation (Hafner et al., 2012). These
oncogenic mosaics were distinct from
previously described ones involving
FGFR3 and PIK3CA, which are seen in
less than half of KEN. Rare KRAS
p.G12D mutations were also found by
Hafner’s group, previously reported in a
clinical case of epidermal nevus with
rhabdomyosarcoma (Bourdeaut et al.,
2010). Various functional assays have
proven that these hotspot RAS mutations
cause constitutive activation of the RAS/
RAF/MAPK pathway (Groesser et al.,
2012; Sun et al., 2013).
Taken together, these studies support
KEN as a ‘‘mosaic RASopathy’’, a term
first introduced by Hafner. This term
expanded on the concept of RASopa-
thies, a heterogeneous collection of
syndromes resulting from germline
mutations in oncogenes involved in
the RAS/RAF/MAPK pathway, including
Costello, Noonan, Cardio–facio–cuta-
neous, and Neurofibromatosis-1 syn-
dromes. In the case of KEN, somatic
mutations in this pathway lead to a
mosaic presentation of a phenotypi-
cally distinct entity with essentially
no clinical overlap with the germline
conditions (Hafner et al., 2012).
Other authors have demonstrated in
parallel that NS is also a mosaic RASo-
pathy. Groesser et al. (2013) reported
that up to 95% of sampled NS harbored
the HRAS mutations, most frequently
again with p.G13R. They also found
KRAS p.G12D mutations on rare
occasions, which have been seen in
KEN as well. Using whole-exome
sequencing, Levinsohn et al. (2013)
examined five index samples of NS and
identified the HRAS p.G13R hotspot
mutation in three specimens, whereas
the two remaining featured two KRAS
mutations, p.G12D and p.G12V. Further
analysis of archival specimens supported
the predominance of HRAS p.G13R in
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all 22 specimens, half of which also had
secondary tumor growth (Levinsohn
et al., 2013). Sun et al. (2013)
reinforced NS as either HRAS or KRAS
mosaics, describing again the HRAS
p.G13R as well as a p.G12D mutation,
seen previously in KEN, and the KRAS
hotspot mutation p.G12D.
Because of the great number of over-
lapping RAS mutations, particularly
HRAS p.G13R and KRAS p.G12D, some
investigators believe KEN and NS to be
the same entity (Sybert, 2010), whose
clinical phenotype is a continuum based
somewhat on the body site. Others feel
that with a proportion of KEN having
mutations outside the RAS pathway,
namely in FGFR3 and PIK3CA, the
mutation spectrum between the two
nevi is in fact distinct (Happle, 2013a).
So far we have only reviewed the
mosaic RASopathies involving epider-
mal (keratinocytic and organoid, includ-
ing sebaceous)-type nevi. Some of the
most recent articles looked into cuta-
neous oncogenic mosaics with a mela-
nocytic component. Groesser et al.
(2013) examined a clinical mosaic that
consisted of both melanocytic (nevus
spilus) and sebaceous (nevus sebace-
Clinical Implications
 The genetic basis for many nevoid proliferations is now known to be
somatic mosaicism.
 A significant proportion of these alterations occur in RAS pathway genes
such as HRAS and KRAS.
 The notion of ‘‘RASopathies’’ should be expanded to include keratinocytic,
sebaceous, and some melanocytic nevi.
Table 1. Summary of studies genotyping the available mosaic phenotypes divided into nevoid types
HRAS KRAS NRAS
Nevus type Study Mutation analysesa G13R G12D G12C Otherb G12D G12V Otherb Otherb
Keratinocytic
KENþurothelial carcinomas Hafner et al.,
2011c
Sanger sequencing G12S — — — —
KEN Hafner et al.,
2012
SNaPshot assay,
Sanger sequencing
21/72 1/72 G12V,
Q61L
1/72 G12D, P34L,
Q61R
FGFR3 (16/72),
PIK3CA (6/72)
KENþ rhabdomyosarcoma Bourdeaut
et al., 2010c
WGA-aCGH 1/1
Sebaceous
Schimmelpenning syndrome,
NS
Groesser et al.,
2012
RAS SNaPshot assay,
Sanger sequencing
1/2
59/65
1/65 1/65 G12S
(3/65),
A11S
1/2
2/65
1/65
NS Levinsohn
et al., 2013d
WES of index cases,
Sanger sequencing
25/27 1/27 1/27
Schimmelpenning syndrome
(index), NS
Sun et al., 2013 WES of index case,
Sanger sequencing
1/1
24/31
1/31 2/31
PPK (nevus spilusþNS) Groesser et al.,
2013
RAS SNaPshot assay,
Sanger sequencing
4/6 G61R
(2/6)
Melanocytic
Agminated segmental nevi Luo et al.,
2011c
Sanger sequencing 1/1 BRAF V600E
Nevus spilusþoverlying
agminated Spitz nevi
Sarin et al.,
2013c
WES-aCGH 1/1 Copy number
increase in chr.
11p in overlying
Spitz nevi
Nevus spilus Sarin et al.,
2014
Sanger sequencing 8/8 — — — —
Nevus spilus-type CMN Kinsler et al.,
2014
WES G13R,
Q61H (2/3)
Abbreviations: CMN, congenital melanocytic nevus; KEN, keratinocytic epidermal nevi; NS, nevus sebaceous; PPK, phakomatosis pigmentokeratotica; WES,
whole-exome sequencing; WGA-aCGH, whole-genome amplication-array comparative genomic hybridization.
aAnalyses techniques are summarized, but may not reflect the breakdown of additional methods used. See original study for details. ‘‘—’’ Indicates genes not
screened.
bMutations listed under other are present in one sample of the total tested only unless otherwise indicated.
cCase report.
dMerged data. Breakdown: 3/5 HRAS G13R (two additional separate sets were 11/11 and 11/11 for this mutation); 1/5 KRAS G12D; and 1/5 KRAS G12V.
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ous) origin, and reported HRAS p.G13R
and p.Q61R mutations in both of these
areas. This demonstrated that perhaps a
common postzygotic activa-
ting HRAS mutation in a multipotent
progenitor cell leads to the phenotype of
phakomatosis pigmentokeratotica by
subsequent epidermal and melanocytic
differentiation. Happle recognized
this as evidence calling into question
the original proposed mechanism of
non-allelic twin spotting for the two
phenotypes presenting so closely on a
background of normal skin (Happle,
2013b).
Solely melanocytic lesions have also
been queried for oncogenic RAS mosai-
cism. Sarin et al. (2013) originally
demonstrated the hotspot HRAS
p.G13R mutation in a patient with
nevus spilus who then developed
secondary agminated Spitz nevi. This
was followed up with a series of eight
cases of nevus spilus who all had the
activating HRAS mutation (Sarin et al.,
2014). Luo et al. (2011) analyzed a case
of segmental agminated nevi and found
concordant BRAF p.V600E mutations in
11/11 nevi within the segment, but
normal BRAF in a nevus outside of the
segment; this suggests that mosaic
RASopathies may extend to include
RAF genes as well.
In this issue of the JID, Kinsler et al.
(2014) explore mosaicism in congenital
melanocytic nevi clustered on a cafe´-
au-lait background, termed nevus
spilus–type CMN. In a series of 200
CMN and NS, Hanayama et al. (2007)
reported that 42% and 62% of CMN
and NS, respectively, followed the lines
of Blaschko; he thus proposed that each
represents a mosaic event. The unique
combined phenotype of the nevus
spilus–type CMN delivers the opportu-
nity to demonstrate the theory in a
unifying manner. Kinsler et al. (2014)
found NRAS mutations p.Q61H and
p.G13R, which are expectedly distinct
from RAS mutations in KEN and NS, but
also differ from those in nevus spilus and
are unreported in traditional CMN. They
thus characterize the nevus spilus–type
CMN as a genotypically and phenotypi-
cally distinct mosaic RASopathy.
Kinsler et al. (2014) were able to
demonstrate NRAS mutations selecti-
vely in the pigmented macular back-
ground and the overlying CMN, without
a secondary mutation identified. This
is reflective of many other authors’
attempts to identify the secondary
event in multistep tumorigenesis that is
responsible for the loss of heterozy-
gosity. This may explain the develop-
ment of additional phenotypic ‘‘layers’’
in a lesion or the development of
secondary tumors. In Sarin’s case, the
agminated Spitz nevi overlying a
nevus spilus did demonstrate additional
copy number gain in chromosome
11p, where HRAS is located. This is a
well-known chromosomal anomaly
seen in both sporadic and agminated
Spitz nevi (Sarin et al., 2013). Kinsler
et al. (2014) commented on the
possibility of copy number changes or
translocation events that would not be
recognized with their current analysis
pipeline. Perhaps this also rings true for
NS and KEN that develop secondary
tumors, because recent studies have
not been able to find additional
mutations in RAS and other common
oncogenes when analyzing secondary
lesions (Groesser et al., 2013; Levinsohn
et al., 2013).
Many authors have commented on
the phenomenon of one postzygotic
mutation in a multipotent progenitor
cell affecting differing tissues and
resulting in contRASting phenotypes,
i.e., ‘‘phenotypic pleiotropy’’ (Groesser
et al., 2012). Timing of the mutational
event and subsequent cross talk with the
tissue microenvironment is likely what
influences the same heterozygous state
to manifest distinctly. Mosaic RASopa-
thies have presented in such pleomor-
phic phenotypes as combinations
featuring cutaneous and extracutaneous
tissue (e.g., Shimmelpenning syndrome
with its associated neurological, ocular,
and skeletal defects), KEN with rhabdo-
myosarcoma, and KEN or CMN with
skeletal lesions and hypophosphatemia
(Bourdeaut et al., 2010; Groesser et al.,
2012; Lim et al., 2014). If the postzy-
gotic event occurs later on, after
differentiation of ectodermal tissue, it
may result in a mosaic involving mela-
nocytic and epidermal components
such as in phakomatosis pigmento-
vascularis (Groesser et al., 2013).
Finally, if the event occurs after
epidermal differentiation, one may
observe overlapping phenotypes of
KEN and NS, suggesting that both are
the same genotypic entity (Levinsohn
et al., 2013).
The recent literature has greatly
expanded the arena of RASopathies to
include various nevoid proliferations
as ‘‘mosaic RASopathies’’. The many
junctions of their mutational profiles
in juxtaposition to their distinctive
phenotypic forms have revealed their
potential mechanisms of development.
Additional investigation into these
mosaic RASopathies promises to reveal
mechanisms of cutaneous tumorigenesis
as well as furthering our understanding
of an individual’s overall oncogenic
risk.
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